A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Dose, Dose-Escalation and Food-Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB099280 When Administered Orally to Healthy Adult Participants
Latest Information Update: 11 Nov 2019
At a glance
- Drugs INCB 099280 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
Most Recent Events
- 08 Nov 2019 New trial record